哌啶,4-甲基-1-(2-苯基乙基)- | 138878-98-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 哌啶,4-甲基-1-(2-苯基乙基)-
• 英文名称: 4-methyl-1-phenethylpiperidine
• 英文别名: 4-Methyl-1-phenethyl-piperidine；4-methyl-1-(2-phenylethyl)piperidine
• CAS: 138878-98-5
• 化学式: C₁₄H₂₁N
• 分子量: 203.327
• InChiKey: HRWOMUZLXQICPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-甲基戊二酸 在 1,4-二氧六环 、 copper oxide-chromium oxide 、 硫酸 作用下， 250.0 ℃ 、39.22 MPa 条件下， 生成 哌啶,4-甲基-1-(2-苯基乙基)-
  参考文献：
  名称：

  Paden; Adkins, Journal of the American Chemical Society, 1936, vol. 58, p. 2493

  摘要：

  DOI：

文献信息

• Hydroamination of terminal alkynes with secondary amines catalyzed by copper: regioselective access to amines
  作者：Janet Bahri、Rémi Blieck、Bassem Jamoussi、Marc Taillefer、Florian Monnier

  DOI：10.1039/c5cc02677f

  日期：——

  A simple and convenient copper-catalyzed hydroamination of arylacetylenes with secondary amines has been performed giving a simple access to aliphatic amines after reduction of the hydroaminated products (E-enamines).

  一种简单方便的铜催化芳基乙炔与二级胺的氢胺化反应已经进行，经过氢胺化产物（E-烯胺）还原后，简单地获得脂肪胺的途径。
• NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF
  申请人：FUJIFILM Corporation

  公开号：US20160168139A1

  公开（公告）日：2016-06-16

  There is provided a morpholine derivative represented by General Formula [1A] or a salt thereof. (In the formula, a ring A represents a ring represented by General Formula [I]; * represents a bonding position; Z 2 represents CH or the like; Z 1 represents CR 6 or the like; R 6 represents a hydrogen atom or the like; X 1 represents CHR 7 or the like; R 7 represents a hydrogen atom or the like; X 2 represents CH 2 or the like; R 1 and R 2 are the same as or different from each other, and each of R 1 and R 2 represents a hydrogen atom or the like; R 3 , R 4 , and R 5 are the same as or different from each other, and each of R 3 , R 4 , and R 5 represents a hydrogen atom, NR a R b , or the like; and each of R a and R b represents a hydrogen atom, a C 1-8 alkyl group which may have a substituent, or the like.)

  提供一种由通用式[1A]表示的吗啉衍生物或其盐。 （在该式中，环A代表由通用式[I]表示的环；*代表连接位置；Z 2 代表CH或类似物；Z 1 代表CR 6 或类似物；R 6 代表氢原子或类似物；X 1 代表CHR 7 或类似物；R 7 代表氢原子或类似物；X 2 代表CH 2 或类似物；R 1 和R 2 相同或不同，且R 1 和R 2 中的每一个代表氢原子或类似物；R 3 ，R 4 和R 5 相同或不同，且R 3 ，R 4 和R 5 中的每一个代表氢原子，NR a R b 或类似物；R a 和R b 中的每一个代表氢原子，可能具有取代基的C 1-8 烷基基团，或类似物。）
• [EN] META SUBSTITUTED PHENYLPYRAZOLO- AND PHENYLPYRROLO- PYRIDAZINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN<br/>[FR] DÉRIVÉS DE PHÉNYLPYRAZOLO- ET PHÉNYLPYRROLO-PYRIDAZINE MÉTA-SUBSTITUÉS AYANT UNE ACTIVITÉ MULTIMODALE CONTRE LA DOULEUR
  申请人：ESTEVE LABOR DR

  公开号：WO2018100041A1

  公开（公告）日：2018-06-07

  The present invention relates to meta substituted phenylpyrazolo-and phenylpyrrolo-pyridazine derivatives of formula (I) having dual pharmacological activity towards both the a28 subunit, in particular the a28-l subunit, of the voltage-gated calcium channel and the NET receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

  本发明涉及具有对电压门控钙通道的a28亚基，特别是a28-l亚基，以及NET受体具有双重药理活性的式(I)的取代苯基吡唑啉和吡咯吡啶并吡啉衍生物，以及这些化合物的制备过程、包含它们的药物组合物，以及它们在治疗中的用途，特别是用于疼痛治疗。
• A potassium magnesiate complex: Synthesis, structure and catalytic intermolecular hydroamination of styrenes
  作者：Xiang-Yu Zhang、Dan-Dan Zhai、Yu-Feng Liu、Bing-Tao Guan

  DOI：10.1016/j.jorganchem.2022.122254

  日期：2022.3

  which revealed interactions between potassium and magnesium atoms via amide and benzyl group. The potassium magnesiate complex showed dramatic bimetallic synergistic effect in the catalytic intermolecular hydroamination of styrenes.

  通过简单地将氨基镁和苄基钾在甲苯中混合，合成了一种新的异质双金属镁酸钾配合物KMg[N(SiMe 3 ) 2 ] 2 Bn (Bn = PhCH 2 -)。还制备了 TMEDA 配位的镁酸钾复合物，其固体结构通过 X 射线晶体衍射表征，揭示了钾和镁原子之间通过酰胺和苄基的相互作用。镁酸钾配合物在苯乙烯的催化分子间加氢胺化中表现出显着的双金属协同效应。
• NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE
  申请人：Nakamura Tetsuya

  公开号：US20090239860A1

  公开（公告）日：2009-09-24

  The present invention provides compounds represented by general formula (I): or pharmaceutical acceptable salts thereof, wherein R 1 is hydrogen or lower alkyl; R 2 is lower alkyl, halo-lower alkyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, arylalkenyl, aryloxy-lower alkyl, heteroaryl, heteroaryl-lower alkyl, etc; R 3 , R 4 , R 5 and R 6 are each hydrogen, halogen, cyano, lower alkyl, halo-lower alkyl, lower alkoxy, hydroxy, aryl, etc; provided that at least one of R 3 , R 4 , R 5 and R 6 is other than hydrogen. Compound (I) of the present invention shows a potent adenosine A 2A receptor antagonistic activity, and are useful for treating or preventing a disease mediated by adenosine A 2A receptors such as motor function disorders, depression, anxiety disorders, cognitive function disorders, cerebral ischemia disorders, restless legs syndrome and the like.

  本发明提供了通式(I)所表示的化合物或其药物可接受的盐，其中R1是氢或低碳基；R2是低碳基，卤代低碳基，环烷基，杂环烷基，芳基，芳基烷基，芳基烯基，芳氧基-低碳基，杂芳基，杂芳基-低碳基等；R3、R4、R5和R6均为氢、卤素、氰基、低碳基、卤代低碳基、低碳氧基、羟基、芳基等；其中至少有一个R3、R4、R5和R6不是氢。本发明的化合物(I)表现出强大的腺苷A2A受体拮抗活性，并且可用于治疗或预防由腺苷A2A受体介导的疾病，例如运动功能障碍、抑郁症、焦虑症、认知功能障碍、脑缺血性疾病、不宁腿综合征等。